Viewing Study NCT02431559

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 2:49 PM
Ignite Modification Date: 2026-02-11 @ 2:15 AM
Study NCT ID: NCT02431559
Status: COMPLETED
Last Update Posted: 2022-10-10
First Post: 2015-04-27
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer
Sponsor: Ludwig Institute for Cancer Research
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Ovarian Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Ovarian Cancer View
None Motolimod View
None Immunotherapy View
None PD-L1 View
None MEDI4736 View
None Pegylated View
None Liposomal View
None Doxorubicin View
None PLD View
None TLR-8 View
None Durvalumab View